JOP20210279A1 - طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي - Google Patents

طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي

Info

Publication number
JOP20210279A1
JOP20210279A1 JOP/2021/0279A JOP20210279A JOP20210279A1 JO P20210279 A1 JOP20210279 A1 JO P20210279A1 JO P20210279 A JOP20210279 A JO P20210279A JO P20210279 A1 JOP20210279 A1 JO P20210279A1
Authority
JO
Jordan
Prior art keywords
treatment
psoriatic arthritis
subjects
methods
hum13b8
Prior art date
Application number
JOP/2021/0279A
Other languages
Arabic (ar)
English (en)
Inventor
Kirti Wardhaman Ganorkar
Anil Raghavan
Atul Mathuradas Raut
Siu-Long Yao
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of JOP20210279A1 publication Critical patent/JOP20210279A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JOP/2021/0279A 2019-04-15 2020-04-15 طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي JOP20210279A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Publications (1)

Publication Number Publication Date
JOP20210279A1 true JOP20210279A1 (ar) 2023-01-30

Family

ID=72837755

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0279A JOP20210279A1 (ar) 2019-04-15 2020-04-15 طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي

Country Status (16)

Country Link
US (1) US20220298233A1 (enExample)
EP (1) EP3956357A4 (enExample)
JP (2) JP7628962B2 (enExample)
KR (1) KR20210140780A (enExample)
CN (1) CN113825768A (enExample)
AU (1) AU2020259375A1 (enExample)
BR (1) BR112021020612A2 (enExample)
CA (1) CA3143604A1 (enExample)
IL (1) IL287213A (enExample)
JO (1) JOP20210279A1 (enExample)
MA (1) MA55729A (enExample)
MX (1) MX2021012652A (enExample)
MY (1) MY210310A (enExample)
PH (1) PH12021552536A1 (enExample)
SG (1) SG11202111056YA (enExample)
WO (1) WO2020212874A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202521154A (zh) * 2023-08-11 2025-06-01 大陸商信達生物製藥（蘇州）有限公司 既往接受生物製劑治療斑塊狀銀屑病的受試者轉用抗ＩＬ２３ｐ１９抗體治療斑塊狀銀屑病的方法
WO2025051249A1 (zh) * 2023-09-07 2025-03-13 信达生物制药(苏州)有限公司 一种重组抗IL-23p19抗体治疗中重度银屑病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
BRPI0807710B1 (pt) * 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
WO2010027766A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
PT2635601T (pt) * 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
WO2014004436A2 (en) * 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies

Also Published As

Publication number Publication date
BR112021020612A2 (pt) 2021-12-28
MX2021012652A (es) 2022-01-24
CN113825768A (zh) 2021-12-21
KR20210140780A (ko) 2021-11-23
MY210310A (en) 2025-09-10
PH12021552536A1 (en) 2022-07-04
MA55729A (fr) 2022-02-23
JP2025069284A (ja) 2025-04-30
US20220298233A1 (en) 2022-09-22
JP2022529266A (ja) 2022-06-20
CA3143604A1 (en) 2020-10-22
EP3956357A4 (en) 2023-01-04
EP3956357A1 (en) 2022-02-23
SG11202111056YA (en) 2021-11-29
WO2020212874A1 (en) 2020-10-22
IL287213A (en) 2021-12-01
JP7628962B2 (ja) 2025-02-12
AU2020259375A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
JOP20220161A1 (ar) جسم مضاد لـ lilrb1 واستخداماته
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
EA201890382A1 (ru) Конструкции антител для cd70 и cd3
EA201890383A8 (ru) Конструкции биспецифических антител, связывающиеся с мезотелином и кд3 (cd3)
BR112015024553A2 (pt) anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio
EA201890390A8 (ru) БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3
EA201992546A1 (ru) Средства на основе антител к cd33
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2021004114A (es) Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
AR105335A1 (es) Anticuerpos monoclonales anti-sortilina
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
EA202192101A1 (ru) Соединения и их применение
MX2024009153A (es) Metodos para el tratamiento de sujetos con psoriasis en placas del cuero cabelludo
MX2021007488A (es) Uso de anticuerpos il-1 beta en el tratamiento o prevencion del sindrome mielodisplasico.
EA201891594A1 (ru) Антитела к il-17c
JOP20210279A1 (ar) طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي